Complementarity determining regions in SARS-CoV-2 hybrid immunity
Pre-vaccination SARS-CoV-2 infection can boost protection elicited by COVID-19 vaccination and post-vaccination breakthrough SARS-CoV-2 infection can boost existing immunity conferred by COVID-19 vaccination. Such ‘hybrid immunity’ is effective against SARS-CoV-2 variants. In order to understand ‘hy...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1050037/full |
| _version_ | 1797901713342988288 |
|---|---|
| author | Glynis Frans Doreen Dillaerts Tom Dehaemers Jan Van Elslande Jonas De Leeuw Lise Boon Wim Maes Nico Callewaert Bas Calcoen Lina Ancheva Maaike Cockx Nick Geukens Kusay Arat Rita Derua Rita Derua Pieter Vermeersch Pieter Vermeersch Sebastien Christian Carpentier Xavier Bossuyt Xavier Bossuyt |
| author_facet | Glynis Frans Doreen Dillaerts Tom Dehaemers Jan Van Elslande Jonas De Leeuw Lise Boon Wim Maes Nico Callewaert Bas Calcoen Lina Ancheva Maaike Cockx Nick Geukens Kusay Arat Rita Derua Rita Derua Pieter Vermeersch Pieter Vermeersch Sebastien Christian Carpentier Xavier Bossuyt Xavier Bossuyt |
| author_sort | Glynis Frans |
| collection | DOAJ |
| description | Pre-vaccination SARS-CoV-2 infection can boost protection elicited by COVID-19 vaccination and post-vaccination breakthrough SARS-CoV-2 infection can boost existing immunity conferred by COVID-19 vaccination. Such ‘hybrid immunity’ is effective against SARS-CoV-2 variants. In order to understand ‘hybrid immunity’ at the molecular level we studied the complementarity determining regions (CDR) of anti-RBD (receptor binding domain) antibodies isolated from individuals with ‘hybrid immunity’ as well as from ‘naive’ (not SARS-CoV-2 infected) vaccinated individuals. CDR analysis was done by liquid chromatography/mass spectrometry-mass spectrometry. Principal component analysis and partial least square differential analysis showed that COVID-19 vaccinated people share CDR profiles and that pre-vaccination SARS-CoV-2 infection or breakthrough infection further shape the CDR profile, with a CDR profile in hybrid immunity that clustered away from the CDR profile in vaccinated people without infection. Thus, our results show a CDR profile in hybrid immunity that is distinct from the vaccination-induced CDR profile. |
| first_indexed | 2024-04-10T09:06:14Z |
| format | Article |
| id | doaj.art-128c3bf6fa72485fa13dcf0c22736c77 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T09:06:14Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-128c3bf6fa72485fa13dcf0c22736c772023-02-21T07:08:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.10500371050037Complementarity determining regions in SARS-CoV-2 hybrid immunityGlynis Frans0Doreen Dillaerts1Tom Dehaemers2Jan Van Elslande3Jonas De Leeuw4Lise Boon5Wim Maes6Nico Callewaert7Bas Calcoen8Lina Ancheva9Maaike Cockx10Nick Geukens11Kusay Arat12Rita Derua13Rita Derua14Pieter Vermeersch15Pieter Vermeersch16Sebastien Christian Carpentier17Xavier Bossuyt18Xavier Bossuyt19Department of Laboratory Medicine, University Hospitals Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumDepartment of Laboratory Medicine, University Hospitals Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumPharmAbs: The KU Leuven Antibody Center, KU Leuven, Leuven, BelgiumClinical Laboratory, AZ Groeninge Hospital, Kortrijk, BelgiumLaboratory for Thrombosis Research, KU Leuven Kulak Kortrijk, Kortrijk, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumPharmAbs: The KU Leuven Antibody Center, KU Leuven, Leuven, BelgiumSyBioMa, KU Leuven, Leuven, BelgiumSyBioMa, KU Leuven, Leuven, BelgiumDepartment of Molecular and Cellular Medicine, Laboratory of Protein Phosphorylation and Proteomics, KU Leuven, Leuven, BelgiumDepartment of Laboratory Medicine, University Hospitals Leuven, Leuven, BelgiumDepartment of Cardiovascular Sciences, KU Leuven, Leuven, BelgiumSyBioMa, KU Leuven, Leuven, BelgiumDepartment of Laboratory Medicine, University Hospitals Leuven, Leuven, BelgiumClinical and Diagnostic Immunology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, BelgiumPre-vaccination SARS-CoV-2 infection can boost protection elicited by COVID-19 vaccination and post-vaccination breakthrough SARS-CoV-2 infection can boost existing immunity conferred by COVID-19 vaccination. Such ‘hybrid immunity’ is effective against SARS-CoV-2 variants. In order to understand ‘hybrid immunity’ at the molecular level we studied the complementarity determining regions (CDR) of anti-RBD (receptor binding domain) antibodies isolated from individuals with ‘hybrid immunity’ as well as from ‘naive’ (not SARS-CoV-2 infected) vaccinated individuals. CDR analysis was done by liquid chromatography/mass spectrometry-mass spectrometry. Principal component analysis and partial least square differential analysis showed that COVID-19 vaccinated people share CDR profiles and that pre-vaccination SARS-CoV-2 infection or breakthrough infection further shape the CDR profile, with a CDR profile in hybrid immunity that clustered away from the CDR profile in vaccinated people without infection. Thus, our results show a CDR profile in hybrid immunity that is distinct from the vaccination-induced CDR profile.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1050037/fullSARS-CoV-2COVID-19hybrid immunitycomplementary determining regionvaccination |
| spellingShingle | Glynis Frans Doreen Dillaerts Tom Dehaemers Jan Van Elslande Jonas De Leeuw Lise Boon Wim Maes Nico Callewaert Bas Calcoen Lina Ancheva Maaike Cockx Nick Geukens Kusay Arat Rita Derua Rita Derua Pieter Vermeersch Pieter Vermeersch Sebastien Christian Carpentier Xavier Bossuyt Xavier Bossuyt Complementarity determining regions in SARS-CoV-2 hybrid immunity Frontiers in Immunology SARS-CoV-2 COVID-19 hybrid immunity complementary determining region vaccination |
| title | Complementarity determining regions in SARS-CoV-2 hybrid immunity |
| title_full | Complementarity determining regions in SARS-CoV-2 hybrid immunity |
| title_fullStr | Complementarity determining regions in SARS-CoV-2 hybrid immunity |
| title_full_unstemmed | Complementarity determining regions in SARS-CoV-2 hybrid immunity |
| title_short | Complementarity determining regions in SARS-CoV-2 hybrid immunity |
| title_sort | complementarity determining regions in sars cov 2 hybrid immunity |
| topic | SARS-CoV-2 COVID-19 hybrid immunity complementary determining region vaccination |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1050037/full |
| work_keys_str_mv | AT glynisfrans complementaritydeterminingregionsinsarscov2hybridimmunity AT doreendillaerts complementaritydeterminingregionsinsarscov2hybridimmunity AT tomdehaemers complementaritydeterminingregionsinsarscov2hybridimmunity AT janvanelslande complementaritydeterminingregionsinsarscov2hybridimmunity AT jonasdeleeuw complementaritydeterminingregionsinsarscov2hybridimmunity AT liseboon complementaritydeterminingregionsinsarscov2hybridimmunity AT wimmaes complementaritydeterminingregionsinsarscov2hybridimmunity AT nicocallewaert complementaritydeterminingregionsinsarscov2hybridimmunity AT bascalcoen complementaritydeterminingregionsinsarscov2hybridimmunity AT linaancheva complementaritydeterminingregionsinsarscov2hybridimmunity AT maaikecockx complementaritydeterminingregionsinsarscov2hybridimmunity AT nickgeukens complementaritydeterminingregionsinsarscov2hybridimmunity AT kusayarat complementaritydeterminingregionsinsarscov2hybridimmunity AT ritaderua complementaritydeterminingregionsinsarscov2hybridimmunity AT ritaderua complementaritydeterminingregionsinsarscov2hybridimmunity AT pietervermeersch complementaritydeterminingregionsinsarscov2hybridimmunity AT pietervermeersch complementaritydeterminingregionsinsarscov2hybridimmunity AT sebastienchristiancarpentier complementaritydeterminingregionsinsarscov2hybridimmunity AT xavierbossuyt complementaritydeterminingregionsinsarscov2hybridimmunity AT xavierbossuyt complementaritydeterminingregionsinsarscov2hybridimmunity |